Кристи Фанк - Грудь. Руководство пользователя [litres]

M. Ramalho et al., “Cognitive Impairment in the First Year after Breast Cancer Diagnosis: A Prospective Cohort Study,” The Breast 32 (2017): 173–178.

D. H. Silverman et al. “Abnormal Regional Brain Metabolism in Breast Cancer Survivors after Adjuvant Chemotherapy Is Associated with Cognitive Changes,” Proceedings of the American Society of Clinical Oncology 22 (2003).

S. B. Schagen et al., “Change in Cognitive Function after Chemotherapy: A Prospective Longitudinal Study in Breast Cancer Patients,” Journal of the National Cancer Institute 98, no. 23 (2006): 1742–1745.

X. Chen et al., “Decision-Making Impairments in Breast Cancer Patients Treated with Tamoxifen,” Hormones and Behavior 66, no. 2 (2014): 449–456.

T. A. Ahles and A. J. Saykin, “Candidate Mechanisms for Chemotherapy-Induced Cognitive Changes,” Nature Reviews: Cancer 7, no. 3 (March 2007): 192–201.

R. J. Ferguson et al., “Cognitive‐Behavioral Management of Chemotherapy‐Related Cognitive Change,” Psycho‐Oncology 16, no. 8 (2007): 772–777.

Early Breast Cancer Trialists’ Collaborative Group, “Tamoxifen for Early Breast Cancer: An Overview of the Randomised Trials,” The Lancet 351, no. 9114 (May 1998): 1451–1467.

M. Schaapveld et al., “Risk of New Primary Nonbreast Cancers after Breast Cancer Treatment: A Dutch Population-Based Study,” Journal of Clinical Oncology 26, no. 8 (March 2008): 1239–1246.

E. Diamandidou et al., “Treatment-Related Leukemia in Breast Cancer Patients Treated with Fluorouracil-doxorubicin-cyclophosphamide Combination Adjuvant Chemotherapy: The University of Texas M. D. Anderson Cancer Center Experience,” Journal of Clinical Oncology 14, no. 10 (October 1996): 2722–2730.

T. Grantzau and J. Overgaard, “Risk of Second Non-breast Cancer among Patients Treated with and without Postoperative Radiotherapy for Primary Breast Cancer: A Systematic Review and Meta-analysis of Population-Based Studies Including 522,739 Patients,” Radiotherapy and Oncology 121, no. 3 (2016): 402–413.

H. G. Björneklett et al., “A Randomised Controlled Trial of Support Group Intervention after Breast Cancer Treatment: Results on Anxiety and Depression,” Acta Oncologica 51, no. 2 (February 2012): 198–207; H. G. Björneklett et al., “LongTerm Follow-Up of a Randomized Study of Support Group Intervention in Women with Primary Breast Cancer,” Journal of Psychosomatic Research 74, no. 4 (April 2013): 346–353.

R. Jagsi et al., “Patient-Reported Quality of Life and Satisfaction with Cosmetic Outcomes after Breast Conservation and Mastectomy with and without Reconstruction: Results of a Survey of Breast Cancer Survivors,” Annals of Surgery 261, no. 6 (2015): 1198.

M. E. Mast, “Survivors of Breast Cancer: Illness Uncertainty, Positive Reappraisal, and Emotional Distress,” Oncology Nursing Forum 25, no. 3 (April 1998): 555–562.

R. R. Bouknight, C. J. Bradley, and Z. Luo, “Correlates of Return to Work for Breast Cancer Survivors,” Journal of Clinical Oncology 24, no. 3 (2006): 345–353.

J. H. Lee et al., “US Screening for Detection of Nonpalpable Locoregional Recurrence after Mastectomy,” European Journal of Radiology 82, no. 3 (2013): 485–489.

I. L. Wapnir et al., “Prognosis after Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials,” Journal of Clinical Oncology 24, no. 13 (May 2006): 2028–2037.

S. J. Anderson et al., “Prognosis after Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer,” Journal of Clinical Oncology 27, no. 15 (2009): 2466–2473.

M. Trombetta et al., “Breast Conservation Surgery and Interstitial Brachytherapy in the Management of Locally Recurrent Carcinoma of the Breast: The Allegheny General Hospital Experience,” Brachytherapy 7, no. 1 (January – March 2008): 29–36; T. E. Alpert et al., “Ipsilateral Breast Tumor Recurrence after Breast Conservation Therapy: Outcomes of Salvage Mastectomy vs. Salvage Breast-Conserving Surgery and Prognostic Factors for Salvage Breast Preservation,” International Journal of Radiation Oncology * Biology * Physics 63 (2005): 845–851.

J. O’Shaughnessy, “Extending Survival with Chemotherapy in Metastatic Breast Cancer,” The Oncologist 10, no. 3 (2005): 20–29.

A. B. Mariotto et al., “Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States,” Cancer Epidemiology and Prevention Biomarkers 26, no. 6 (2017): 809–815.

Early Breast Cancer Trialists’ Collaborative Group, “Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” The Lancet 365, no. 9472 (2005): 1687–1617.

F. J. Esteva et al., “Molecular Prognostic Factors for Breast Cancer Metastasis and Survival,” Seminars in Radiation Oncology 12, no. 4 (Philadelphia: W. B. Saunders, 2002).

L. Natarajan et al., “Time-Varying Effects of Prognostic Factors Associated with Disease-Free Survival in Breast Cancer,” American Journal of Epidemiology 169, no. 12 (2009): 1463–1470.

W. F. Anderson, I. Jatoi, and S. S. Devesa, “Distinct Breast Cancer Incidence and Prognostic Patterns in the NCI’s SEER Program: Suggesting a Possible Link between Etiology and Outcome,” Breast Cancer Research and Treatment 90, no. 2 (2005): 127–137.

C. Fan et al., “Concordance among Gene-Expression – Based Predictors for Breast Cancer,” New England Journal of Medicine 355, no. 6 (2006): 560–569.

S. Paik et al., “A Multigene Assay to Predict Recurrence of Tamoxifen-treated, Node-Negative Breast Cancer,” New England Journal of Medicine 351, no. 27 (2004): 2817–2826.

C. Desmedt et al., “Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series,” Clinical Cancer Research 13, no. 11 (June 2007): 3207–3214.

S. Friberg and S. Mattson, “On the Growth Rates of Human Malignant Tumors: Implications for Medical Decision Making,” Journal of Surgical Oncology 65, no. 4 (1997): 284–297.

M. Colleoni et al., “Annual Hazard Rates of Recurrence for Breast Cancer during 24 Years of Follow-Up: Results from the International Breast Cancer Study Group Trials I to V,” Journal of Clinical Oncology 34, no. 9 (2016): 927–935.